Kiek dividendų moka Sinphar Pharmaceutical Co 2024?
Pagal paskutinę informaciją nuo lapkritis 2024, Sinphar Pharmaceutical Co per paskutinius 12 mėnesių mokėjo bendrą dividendą, kuris sudarė 1,00 TWD už akciją. Esant dabartiniam Sinphar Pharmaceutical Co kursui 30,45 TWD, tai atitinka 3,28 % dividendų grąžą.
Dividendai mokami kartus per metus.
3,28 % Dividendo grąža | = | 1,00 TWD Dividendas | 30,45 TWD akcijų kaina |
|
Ar Sinphar Pharmaceutical Co dividendai yra saugūs?
Sinphar Pharmaceutical Co kasmet didina dividendus jau 1 metus.
Per pastaruosius 10 metus Sinphar Pharmaceutical Co kasmet 6,471 % padidėjo.
Per 5 metų laikotarpį augo išmokos padidėjo 37,973 %.
Analitikai prognozuoja, kad einamaisiais verslo metais Dividendų mažinimas bus −100,000%.
Sinphar Pharmaceutical Co Aktienanalyse
Ką daro Sinphar Pharmaceutical Co?
Sinphar Pharmaceutical Co Ltd is a Taiwanese company specializing in the pharmaceutical industry, founded in 1970. It is a leading manufacturer of pharmaceuticals and specializes in the production of generics and branded drugs.
The company is headquartered in Taipei, Taiwan and has become an important player in the global pharmaceutical market in recent years. It has several divisions specializing in the production of drugs, supplements, and medical devices.
Sinphar has two main business models, including the development of its own products and the licensing of products from other companies. The company has its own manufacturing facility, certified to FDA and GMP (Good Manufacturing Practice) standards, allowing it to produce high-quality drugs.
Sinphar offers a wide range of products, including pharmaceuticals, supplements, medical devices, and other health products. It also has a variety of products focusing on the treatment of diseases such as diabetes, cancer, heart disease, and other conditions.
The company has several divisions specializing in the development of drugs and medical devices. It also has an extensive research and development department focusing on the development of new drugs and medical devices. Sinphar works closely with various academic institutions and research institutes to stay updated on the latest developments in medicine and utilize the latest technologies.
The company has several subsidiaries, including ones in the USA, China, and Singapore. Through these subsidiaries, the company has access to various local markets and can sell its products worldwide.
Sinphar has received several awards and recognition for its work in recent years. In 2019, the company was awarded by the Taiwanese Ministry of Education for its exceptional performance in the development of medical devices and pharmaceutical products.
Overall, Sinphar Pharmaceutical Co Ltd is a leading player in the pharmaceutical industry with a long history of developing high-quality drugs and medical devices. It specializes in the production of generics and branded drugs and has several divisions specializing in the development of drugs and medical devices. With its subsidiaries and research and development department, the company is well positioned to continue growing and evolving in the future. Sinphar Pharmaceutical Co yra viena populiariausių įmonių Eulerpool.com svetainėje.Akcijų taupymo planai siūlo patrauklią galimybę investuotojams ilgalaikėje perspektyvoje kurti turtą. Vienas pagrindinių privalumų yra vadinamasis vidutinės išlaidos efektas: reguliariai investuojant fiksuotą sumą į akcijas arba akcijų fondus, automatiškai perkama daugiau dalinių vertybių popierių, kai kainos yra žemos, ir mažiau – kai jos aukštos. Tai gali lemti palankesnę vidutinę dalies kainą per laiką. Be to, akcijų taupymo planai suteikia galimybę ir smulkiesiems investuotojams patekti į brangias akcijas, nes jie gali dalyvauti jau su mažomis sumomis. Reguliarus investavimas taip pat skatina disciplinuotą investavimo strategiją ir padeda išvengti emociškai pagrįstų sprendimų, pavyzdžiui, impulsyvaus pirkimo ar pardavimo. Be to, investuotojai gauna naudos iš potencialaus akcijų vertės augimo bei iš dividendų, kurie gali būti reinvestuoti, kas sustiprina sudėtinio palūkanų efektą ir taip skatina investuoto kapitalo augimą.